EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020–2024)

Filippos Panteleimon Chatzipieris iD, Errikos Petsas iD, George Lambrinidis iD, John M Matsoukas iD, Thomas Mavromoustakos iD

Biomolecules · 22.12.2025 · 16 (1) · 20

DOI: 10.3390/biom16010020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 22.12.2025. Verfasst von Filippos Panteleimon Chatzipieris und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece. Hauptthemen laut MEDLINE: Receptor, Angiotensin, Type 1, Hypertension, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The renin–angiotensin–aldosterone system (RAAS) is essential for controlling blood pressure and maintaining fluid balance, driving significant structural changes throughout the cardiovascular system, including the heart and blood vessels. As a result, the RAAS is a key therapeutic target for various chronic cardiovascular diseases, ranging from arterial hypertension (AH) to heart failure (HF). In this review, one of our objectives is to describe the new evidence over the last 4 years regarding the RAAS. Moreover, we pay attention to the structure and function of the angiotensin II type 1 receptor (AT1R) and its role in hypertension, as well as define its active site. Later, we discuss the most potent, selective inhibitors of AT1 receptors, based on in vitro and in vivo experiments, from 2020 to 2024. Large peptide molecules, small non-peptide-like molecules, and sartan derivatives are analyzed. The low IC50 values of the entities that do not resemble sartans showcase the vast chemical space that can be explored for the creation of more potent antihypertensive medications. We have also employed computational chemistry tools in order to identify key molecular interactions between the compounds of the literature studied in order to elucidate the underlying reasons why these different molecules exhibit variations in their binding energies and overall potency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Angiotensin, Type 1HypertensionAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsDrug DesignHumansRenin-Angiotensin SystemAnimals

Stichwörter der Autor:innen

Structure-Activity Relationship (SAR)active site of AT1Ralternative pathway of RAASangiotensin II type 1 receptor (AT1R)classical pathway of RAAShypertension (HT)novel AT1R antagonists (2020–2024)renin–angiotensin–aldosterone system (RAAS)sartan derivatives

Substanzen

Receptor, Angiotensin, Type 1Angiotensin II Type 1 Receptor BlockersAntihypertensive Agents

Autor:innen und Institutionen

  • Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
  • Division of Medicinal Chemistry, Department of Pharmacy, School of Health Sciences, National & Kapodistrian University of Athens, 15771 Athens, Greece.
  • Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia.
  • Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • NewDrug, P.C., Patras Science Park, 26504 Patras, Greece.
  • Department of Chemistry, University of Patras, 26504 Patras, Greece.

ORCID-Profile: Filippos Panteleimon Chatzipieris, Errikos Petsas, George Lambrinidis, John M Matsoukas, Thomas Mavromoustakos

Zitieren

APA

Chatzipieris, F. P., Petsas, E., Lambrinidis, G., Matsoukas, J. M., & Mavromoustakos, T. (2025). Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020–2024). Biomolecules, 16(1), 20. https://doi.org/10.3390/biom16010020

Vancouver

Chatzipieris FP, Petsas E, Lambrinidis G, Matsoukas JM, Mavromoustakos T. Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020–2024). Biomolecules. 2025;16(1):20. doi:10.3390/biom16010020

BibTeX
@article{Chatzipieris2025,
  author = {Chatzipieris, Filippos Panteleimon and Petsas, Errikos and Lambrinidis, George and Matsoukas, John M and Mavromoustakos, Thomas},
  title = {Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020–2024)},
  journal = {Biomolecules},
  year = {2025},
  volume = {16},
  number = {1},
  pages = {20},
  doi = {10.3390/biom16010020}
}
Kostenlos starten →